Tuberculosis Meningitis: A High-Dose Antibiotic Approach Falls Short
Tuberculosis (TB) is a global health crisis, claiming the lives of approximately 1.4 million people annually out of the 11 million who contract it. Among the most severe complications is TB meningitis, affecting 1-2% of patients when the bacteria invade the brain. Despite antibiotic treatment, this form of meningitis carries a grim prognosis, with around half of the patients dying or enduring permanent disabilities like deafness or paralysis.
In a quest for better outcomes, researchers focused on rifampicin, a crucial antibiotic in TB treatment. Here's where it gets intriguing: Previous studies revealed that rifampicin barely reaches the brain, allowing bacteria to thrive, but higher doses were linked to reduced mortality. This sparked a global effort to explore higher rifampicin dosing.
A groundbreaking study, co-designed by Radboudumc and conducted across Indonesia, Uganda, and South Africa, aimed to determine if a higher rifampicin dose could improve survival rates in TB meningitis. The study involved 499 adults, all receiving the standard four-antibiotic regimen, including rifampicin at 10 mg/kg. Half of the participants received an additional rifampicin dose of up to 35 mg/kg, while the other half received a placebo for eight weeks. The average patient age was 37, with 60% being HIV-positive.
But here's the twist: The study found no survival benefit from the higher rifampicin dose. In some subgroups, there was even an increased risk of death. After six months, 44.6% of the high-dose group had succumbed, compared to 40.7% in the standard group. This higher mortality was most pronounced in the initial weeks after diagnosis.
The researchers, led by internist-infectiologist Reinout van Crevel, acknowledged the disappointment but emphasized the significance of these findings. They are now exploring alternative strategies, focusing on the inflammation in the brain membranes rather than just the bacteria. Initial analyses suggest that the protein TNF, while crucial for clearing bacteria, may also cause severe brain damage.
The controversy: Should TNF inhibitors be introduced earlier in treatment? Current protocols often reserve these drugs for later stages when corticosteroids fail. However, the team has seen promising results with early TNF inhibitor use in their TB center and in Jakarta. The upcoming clinical trial will investigate this controversial approach, potentially offering a new direction in the battle against TB meningitis.
As the medical community awaits these findings, the quest for improved TB meningitis therapies continues, underscoring the complexity of treating this devastating disease.
